BiotechTube
DICE-CRO

DICE-CRO

Ghent, Belgium· Est.
dice-cro.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

DICE-CRO is a specialized, service-oriented Contract Research Organization headquartered in Ghent, Belgium, with a mission to improve medical treatment access through clinical trial excellence. The company boasts a collective experience of over 36 years, having assisted in over 1,250 studies across all phases (I-IV) and various advanced modalities like cell/gene therapy and biologics. It operates as a private, revenue-generating entity, serving an international clientele from the EU, US, and Asia with a focus on complex therapeutic areas. DICE's core value proposition lies in its integrated service offerings from study design through regulatory submission support.

OncologyNeurologyOpthalmologyHaematologyOrphan diseasesEndocrinologyGastroenterologyPneumologyUrologyAutoimmune diseaseDiabetesMetabolic disordersPediatric diseases

Technology Platform

Integrated clinical trial service platform specializing in complex modalities (cell/gene therapy, biologics, immunotherapeutics) and advanced data analysis, including central imaging review and regulatory submission support.

Opportunities

Growing demand for specialized CRO services in complex therapeutic areas (oncology, orphan diseases) and advanced modalities like cell and gene therapy.
Increased outsourcing by biotech sponsors and the need for regulatory strategy expertise present significant growth avenues.
International client base provides a platform for further geographic expansion.

Risk Factors

Faces intense competition from large global CROs and other niche players.
Revenue is susceptible to client concentration and cyclical swings in biopharma R&D spending.
Operational performance and reputation are critical; any significant service failure could severely impact the business.

Competitive Landscape

Operates in the highly fragmented and competitive global CRO market. Competes with large, full-service CROs (e.g., IQVIA, ICON) on select projects and with many other small-to-mid-sized, specialized European CROs. Differentiation is based on therapeutic expertise, service integration, and proficiency in novel therapy areas.

More companies in Small Molecule Drugs →More companies in Belgium →